EBS
EBS clinical trials: Emergent BioSolutions Inc.
Every trial on ClinicalTrials.gov where Emergent BioSolutions Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 64
- Trials linked
- 47
- As lead sponsor
- 17
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
EBS on the catalyst calendar · EBS registry changes
- Primary completion Oct 2008ActualPhase 2NCT00893516CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell LymphomaEmergent BioSolutions · T-cell LymphomaTerminatedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 10, 2022ActualPhase 1NCT05377255Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy AdultsEmergent BioSolutions · Opioid OverdoseCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimateNo phase registeredNCT01374984VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia InfectionEmergent BioSolutions · Complication of Smallpox VaccinationEnrolling by invitationEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 6, 2020ActualPhase 3NCT03877926VELOCITY: An Anthrax Vaccine Clinical StudyEmergent BioSolutions · AnthraxCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2030Sponsor estimateNo phase registeredNCT07478471Observational Study of Raxibacumab in Sporadic Cases of Systemic AnthraxEmergent BioSolutions · Infections, BacterialNot yet recruitingEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimateNo phase registeredNCT03569553A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax PatientsEmergent BioSolutions · Inhalational AnthraxNot yet recruitingEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimateNo phase registeredNCT03569514Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic AnthraxEmergent BioSolutions · AnthraxNot yet recruitingEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2035Sponsor estimatePhase 4NCT02177721Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioEmergent BioSolutions · Infections, BacterialNot yet recruitingEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2028Sponsor estimatePhase 4NCT02051062BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric PatientsEmergent BioSolutions · BotulismEnrolling by invitationEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2036Sponsor estimateNo phase registeredNCT07268612Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.Emergent BioSolutions · AnthraxNot yet recruitingEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 5, 2020ActualPhase 2NCT04067011Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyEmergent BioSolutions · AnthraxCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 29, 2023ActualPhase 1NCT05194358Study of SIAN Nasal Spray in Healthy AdultsEmergent BioSolutions · Cyanide PoisoningCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2013ActualPhase 2NCT01753115Ciprofloxacin BioThrax Co-Administration StudyEmergent BioSolutions · AnthraxCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 28, 2022ActualPhase 1NCT05142306A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected AdultsEmergent BioSolutions · SARS-CoV-2 InfectionCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 27, 2021ActualPhase 1NCT04661839A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy AdultsEmergent BioSolutions · COVID-19CompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 10, 2023ActualPhase 1NCT05155319Universal Influenza A Vaccine in Healthy AdultsEmergent BioSolutions · Human InfluenzaCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 14, 2023ActualPhase 1NCT05935917Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy AdultsEmergent BioSolutions · SmallpoxCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2014ActualNo phase registeredNCT00928577Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)Emergent BioSolutions · SmallpoxCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2017ActualPhase 1NCT02771730Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected AdultsEmergent BioSolutions · Healthy VolunteerTerminatedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2014ActualPhase 1NCT01979406A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate VaccinesEmergent BioSolutions · Anthrax InfectionCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2012ActualNo phase registeredNCT01540929Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military PersonnelEmergent BioSolutions · SmallpoxCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 4, 2019ActualNo phase registeredNCT01395082ACAM2000® Myopericarditis RegistryEmergent BioSolutions · MyocarditisCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2011ActualPhase 1NCT01006798Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1Emergent BioSolutions · Bird FluCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2006ActualPhase 2/Phase 3NCT00877656HuMax-CD4 in Non-Cutaneous T-Cell LymphomaEmergent BioSolutions · T Cell LymphomaCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2009ActualPhase 1NCT00636519Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB MuscleEmergent BioSolutions · Healthy VolunteersCompletedEBSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 39 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner